Defining the clinical course of multiple sclerosis
Results of an international survey
Abstract
Standardization of terminology used to describe the pattern and course of MS is essential for mutual understanding between clinicians and investigators.It is particularly important in design of, and recruitment for, clinical trials statistically powered for expected outcomes for given patient populations with narrowly defined entry criteria. For agents that prove safe and effective for MS, knowledge of the patient populations in definitive clinical trials assists clinicians in determining who may ultimately benefit from use of the medication. An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus. In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS.
NEUROLOGY 1996;46: 907-911
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Matthews WB, Compston A, Allen IV, Martyn CN, eds. McAlpine's multiple sclerosis. Edinburgh: Churchill Livingstone, 1991.
2.
Poser S. Multiple sclerosis: an analysis of 812 cases by means of electronic data processing. Berlin: Springer, 1978.
3.
Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
4.
Phadke JG. Survival patterns and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neuro Neurosurg Psychiatry 1987;50:523-531.
5.
Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
6.
Verjans E, Theys P, Delmotte P, Carton H. Clinical parameters and intrathecal IgG synthesis as prognostic factors in multiple sclerosis. Part I. J Neurol 1983;229:155-165.
7.
Confavreux C, Compston DAS, Hommes OR, et al. EDMUS, a European database for multiple sclerosis. J Neuro Neurosurg Psychiatry 1992;55:671-676.
8.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, placebo-controlled trial. Neurology 1993;43:655-661.
9.
Jacobs LD, Cookfair DL, Rudick RA, et al. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis [abstract]. Ann Neurol 1994;36:259.
10.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
11.
Alter M, Byrne TN, Daube JR, et al. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994;44:1537-1540.
12.
Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
13.
Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chronic Dis 1977;30:819-830.
14.
Thompson AJ, Hutchinson M, Brazil J, et al. A clinical and laboratory study of benign multiple sclerosis. Q J Med 1986;58:69-80.
15.
Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
16.
Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38:1511-1515.
17.
Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988;111:927-929.
18.
Koopmans RA, Li DKB, Oger JJF, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989;26:248-256.
19.
Willoughby EW, Grochowski E, Li DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49.
20.
Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-568.
Information & Authors
Information
Published In
Copyright
Copyright 1996 by Advanstar Communications Inc.
Publication History
Published online: April 1, 1996
Published in print: April 1996
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Stigma in Multiple Sclerosis: A Narrative Review of Current Concepts, Measures, and Findings, International Journal of MS Care, 26, 3, (125-133), (2024).https://doi.org/10.7224/1537-2073.2023-047
- Ataxia in Multiple Sclerosis: From Current Understanding to Therapy, Ataxia - Practice Essentials and Interventions, (2024).https://doi.org/10.5772/intechopen.112013
- Cognitive Impairments in Early Multiple Sclerosis, Multiple Sclerosis - Genetics, Disease Mechanisms and Clinical Developments, (2024).https://doi.org/10.5772/intechopen.108928
- L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review, Nutrients, 16, 8, (1232), (2024).https://doi.org/10.3390/nu16081232
- Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression, Journal of Clinical Medicine, 13, 6, (1813), (2024).https://doi.org/10.3390/jcm13061813
- Blood–Brain Barrier Disruption in Neuroimmunological Disease, International Journal of Molecular Sciences, 25, 19, (10625), (2024).https://doi.org/10.3390/ijms251910625
- Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression, International Journal of Molecular Sciences, 25, 16, (8751), (2024).https://doi.org/10.3390/ijms25168751
- An Overview of Multiple Sclerosis In Vitro Models, International Journal of Molecular Sciences, 25, 14, (7759), (2024).https://doi.org/10.3390/ijms25147759
- Targeting Vascular Impairment, Neuroinflammation, and Oxidative Stress Dynamics with Whole-Body Cryotherapy in Multiple Sclerosis Treatment, International Journal of Molecular Sciences, 25, 7, (3858), (2024).https://doi.org/10.3390/ijms25073858
- In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis, International Journal of Molecular Sciences, 25, 6, (3374), (2024).https://doi.org/10.3390/ijms25063374
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.